Abbott wins FDA clearance for duo of over-the-counter CGMs
June 10, 2024
Abbott (NYSE: ABT)+ today announced FDA clearance for two over-the-counter continuous glucose monitor (CGM) systems, Lingo and Libre Rio.
Abbott (NYSE: ABT)+ today announced FDA clearance for two over-the-counter continuous glucose monitor (CGM) systems, Lingo and Libre Rio.
DeepQure announced today that it received FDA investigational device exemption (IDE) approval for a study of its HyperQure system.
CroíValve today announced favorable patient outcomes in a first-in-human clinical trial of its Duo tricuspid coaptation valve system.